Invention Grant
- Patent Title: OmpA in vaccine compositions and as diagnostic targets
-
Application No.: US15474427Application Date: 2017-03-30
-
Publication No.: US09945851B2Publication Date: 2018-04-17
- Inventor: Jason A. Carlyon
- Applicant: Virginia Commonwealth University
- Applicant Address: US VA Richmond
- Assignee: Virginia Commonwealth University
- Current Assignee: Virginia Commonwealth University
- Current Assignee Address: US VA Richmond
- Agency: Whitham, Curtis & Cook, P.C.
- Main IPC: A61K39/02
- IPC: A61K39/02 ; G01N33/569 ; C07K16/12 ; A61K39/40 ; A61K39/00

Abstract:
Anaplasma Marginale surface protein OmpA and homologous genes from Anaplasmatacaea family members are used in compositions suitable for vaccines to treat or prevent infections caused by tick-born bacteria of the Anaplasmatacaea family. OmpA proteins or peptide fragments may be used in combination with other Anaplasmatacaea surface proteins to elicit an immune response. Furthermore, antibodies to OmpA proteins can be used in diagnostic methods to determine whether an individual has contracted an Anaplasmatacaea infection.
Public/Granted literature
- US20170269080A1 OMPA IN VACCINE COMPOSITIONS AND AS DIAGNOSTIC TARGETS Public/Granted day:2017-09-21
Information query